Long-term neurological consequences following benzodiazepine exposure: A scoping review
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index; 20 of the 98 sources its claims cite were checked for support.
Abstract
Benzodiazepine acute withdrawal syndrome is well known, but the long-term neurological consequences of benzodiazepine exposure are much less familiar. A scoping review was conducted of electronic databases for studies that reported on patient outcomes four or more weeks after complete cessation of benzodiazepine use. Forty-six results were retrieved in total, some of which provided signals for protracted symptoms, often reported as incidental findings, and others that showed benzodiazepine discontinuation was beneficial. Some overlap occurred in the outcomes, but these two groups of studies suggest that the benefits of benzodiazepine discontinuation for many patients tended to obscure the more prolonged, severe, and sometimes debilitating symptoms that persisted for months and years in a subpopulation of patients. The prevalence or trajectory of these enduring symptoms could not be determined from these studies. Further elucidation of the potential neurotoxicity of benzodiazepines is needed to better understand protracted symptoms and their treatment. Clinicians, patients, and the healthcare system must be cognizant of the risks of benzodiazepine exposure beyond two to four weeks.
Overview
CoChat Summary
TL;DR
This scoping review of 46 studies found signals that a subpopulation of patients experiences protracted neurological symptoms persisting four or more weeks after benzodiazepine cessation, while many studies showed discontinuation was beneficial. The prevalence and trajectory of enduring symptoms could not be determined, and the authors call for further research into possible benzodiazepine neurotoxicity.
Key findings
- The search retrieved 14,097 publications and included 46 studies; the Results section reports that 28 of 46 (61%) provided signals of a protracted withdrawal phase, while the Discussion states 27 provided such signals.
- Acute withdrawal occurred in up to 100% of participants in some included studies, whereas prolonged symptoms were reported in approximately 30% of benzodiazepine patients; no incidence or prevalence data were found.
- Fourteen studies (30.4%) had as their main finding that benzodiazepine discontinuation was unproblematic and beneficial, but severe protracted symptoms were also reported, including one study where 100% of 20 benzodiazepine patients had neurologic symptoms at six months after complete cessation and another where 28% required antidepressant therapy at 12 weeks after discontinuation.
- No clear risk or protective factors for protracted symptoms were identified, and no randomized clinical trials were designed with enduring symptoms after complete benzodiazepine cessation as an endpoint.
Methods
- Scoping review following JBI evidence synthesis methodology and PRISMA-ScR guidelines; searches were run in August 2023 and updated in December 2024 across Ovid MEDLINE(R) ALL (1946 to December 6, 2024), Embase, and APA PsycInfo.
- Inclusion criteria were adults ≥18 years who used benzodiazepines for >2 weeks and discontinued for >4 weeks, excluding primary psychotic illness or bipolar disorder; experimental studies, observational studies, case studies/series, and clinical trials were included, while clinical trial registrations, commentaries, editorials, correspondence, reviews, conference abstracts, animal studies, grey literature, and non-English/non-peer-reviewed articles were excluded.
- A descriptive analysis of extracted data was performed to identify article type and summarize relevant data for signals of benzodiazepine-induced neurological dysfunction (BIND).
Limitations
- The paper states that no randomized clinical trials were specifically designed to look for enduring symptoms following complete benzodiazepine cessation, so protracted symptoms observed were signals or incidental findings rather than primary endpoints; prevalence and trajectory could not be determined.
- The paper states that the scoping review allowed a broad range of studies of variable quality, that terminology in the literature was inconsistent, and that grey literature and clinical trial registrations were excluded.
- Evident from the text: the Results and Discussion report different counts of studies providing signals (28 vs. 27), and the included literature was mostly published before 1996 with comparatively few results after 2006.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 PRISMA flow diagram adapted from Covidence review software. [27] At the end of the screening, 46 articles were considered.](https://figures.cochat.ai/paper-figures/a55add5948ef46978fb161aceb3dd5f8/long-term-neurological-consequences-following-benzodiazepine-exposure-a-scoping-figure-1.jpg)


Verification
Claims the paper makes
16 Valid · 2 Not valid · 40 Not checked · 52 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Consistent with other published studies and clinical observations, this scoping review showed that some people can discontinue benzodiazepines even after prolonged exposure with relatively little problem [12,13,23].”
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Discussion
What the sources say
- Partly supportedcites [12] Finlayson A, Macoubrie J, Huff C, Foster D, Martin P. Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey. Ther Adv Psychopharmacol. 2022; 2: 1– 10. PMC9047812 35499041 sourceExperimental — accuracy not yet measured
The Symptoms section reports that 5.2% of respondents who discontinued benzodiazepines said they “withdrew just fine without taper,” and Patient comments include a respondent who reported stopping with no withdrawal problems. Neither passage establishes that those particular respondents had prolonged exposure, so the source supports the possibility of relatively easy discontinuation but not that qualifier. (LLM, conf=0.84)
- Partly supportedcites [13] Ritvo AD, Foster DE, Huff C, Finlayson AJR, Silvernail B, Martin PR. Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey. PLoS One. 2023; 18(6):e0285584. doi: 10.1371/journal.pone.0285584 37384788 PMC10309976 sourceExperimental — accuracy not yet measured
The Results report that 63.2% of survey respondents had completely discontinued benzodiazepines. But the Results and Discussion focus on persistent symptoms and adverse consequences; they do not establish that any respondents discontinued after prolonged exposure with relatively little problem. (LLM, conf=0.81)
- Partly supportedcites [23] Huff C, Finlayson A, Foster D, Martin P. Enduring neurological sequelae of benzodiazepine use: an Internet survey. Ther Adv Psychopharmacol. 2022; 12: 1– 9. PMC9905027 36760692 sourceExperimental — accuracy not yet measured
The Discussion (page not available in our copy) says protracted symptoms do not occur in all benzodiazepine patients and that use often extends for months or years. It does not establish that people with prolonged exposure can discontinue with relatively little problem; absence of protracted symptoms does not rule out other withdrawal difficulties. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A more prolonged condition had been observed decades ago, which typically can be identified after the acute withdrawal syndrome had abated, although nomenclature was inconsistent [23].”
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Background
What the sources say
- Supportedcites [23] Huff C, Finlayson A, Foster D, Martin P. Enduring neurological sequelae of benzodiazepine use: an Internet survey. Ther Adv Psychopharmacol. 2022; 12: 1– 9. PMC9905027 36760692 source
The Introduction describes prolonged benzodiazepine symptoms reported decades ago, including a 1990 account. The Discussion distinguishes acute withdrawal, lasting roughly 10–28 days, from symptoms persisting for months or years, and says the enduring condition historically had several confusing names. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Reports emerged of prolonged problematic clinical symptoms that could persist after completion of the acute withdrawal syndrome, enduring for months or even years after benzodiazepine cessation [12].”
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Background
What the sources say
- Supportedcites [12] Finlayson A, Macoubrie J, Huff C, Foster D, Martin P. Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey. Ther Adv Psychopharmacol. 2022; 2: 1– 10. PMC9047812 35499041 source
The Introduction distinguishes acute withdrawal from possible longer-term consequences after benzodiazepine cessation. The Discussion/conclusion reports that severe symptoms persisted beyond the short-term withdrawal period, sometimes for months or years after discontinuation. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Many respondents stated they had multiple symptoms, with over 40% reporting more than 17 symptoms lasting for over a year.”
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Background
What the sources say
- Partly supportedcites [13] Ritvo AD, Foster DE, Huff C, Finlayson AJR, Silvernail B, Martin PR. Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey. PLoS One. 2023; 18(6):e0285584. doi: 10.1371/journal.pone.0285584 37384788 PMC10309976 sourceExperimental — accuracy not yet measured
The Discussion reports that over 40% of respondents had at least 17 symptoms lasting at least one year after discontinuation. The claim changes both thresholds: “more than 17” excludes respondents with exactly 17 symptoms, and “over a year” excludes symptoms lasting exactly one year. The paper does not give the percentage meeting those stricter thresholds. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The majority of respondents also reported adverse life consequences, such as the loss of home or business or failed relationships [13].”
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Background
What the sources say
- Supportedcites [13] Ritvo AD, Foster DE, Huff C, Finlayson AJR, Silvernail B, Martin PR. Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey. PLoS One. 2023; 18(6):e0285584. doi: 10.1371/journal.pone.0285584 37384788 PMC10309976 source
The Results report that over 90% of respondents attributed at least one general adverse life consequence to benzodiazepine use. Table 3 lists significantly affected relationships, loss of a home, and loss of a business as specific consequences. The majority figure applies to adverse consequences overall, not to each example individually. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
54 more claims · 4 with their cited sources checked
Create a free account to see all 110 claims and to verify the 4 references still open.
- It may state two separate claims as one. 36
- Probably not a substantial claim. 18
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Results > A protracted withdrawal phase
“Twenty-eight of the 46 studies retrieved in the scoping review (61%) provide signals that suggest a protracted withdrawal phase.”
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Discussion
“This scoping review found 46 studies of benzodiazepine cessation, of which 27 provided signals that certain symptoms persisted or emerged more than four weeks after complete benzodiazepine withdrawal.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Results > A protracted withdrawal phase
“Higgitt and colleagues matched nine protracted withdrawal syndrome (PWS) patients to nine anxiety patients not taking any drugs, 13 conversion hysteria patients, and nine healthy controls.”
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Results
“9 prior BZD users with PWS with 3 matched groups:9 conversion disorder pt9 anxiety disorder pt9 healthy volunteers”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Results
“31 BZD users participating in 20 wk taper with counseling to d/c”
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Results
“12/33 pt succeeded with d/c.”
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation
Tricco, A. C., Lillie, E., Zarin, W., O'Brien, K. K., Colquhoun, H., Levac, D., Moher, D., Peters, M. D. J., Horsley, T., Weeks, L., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0850 · Cited by 43,565 · cited 1×
“The scoping review was conducted following JBI evidence synthesis methodology and the PRISMA ScR guidelines [25,26].”
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01626-4 · Cited by 13,874
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2 · Cited by 5,177
Best practice guidance and reporting items for the development of scoping review protocols
Peters, M. D. J., Godfrey, C., McInerney, P., Khalil, H., Larsen, P., Marnie, C., Pollock, D., Tricco, A. C., & Munn, Z. (2022) · JBI Evidence Synthesis · doi:10.11124/jbies-21-00242 · Cited by 1,444
Guidelines for the Rational Use of Benzodiazepines: When and What to Use
Ashton, H. (1994) · Drugs · doi:10.2165/00003495-199448010-00004 · Cited by 593 · cited 1×
“Even short-term use of benzodiazepines may be problematic, because physiologic dependence on benzodiazepines can occur after two to four weeks of use [84–89].”
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573 · cited 1×
“The acute withdrawal syndrome following cessation of chronic benzodiazepine exposure has been well described [19–21].”
Cognitive Effects of Long-Term Benzodiazepine Use: A Meta-Analysis
Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418010-00004 · Cited by 552 · cited 1×
“Meta-analyses of cognitive effects following withdrawal reported problems with recent memory, processing speed, visuo-construction, divided attention, working memory, and sustained attention [17,18].”
Principles of pharmacology : the pathophysiologic basis of drug therapy
Golan, D. E., & Tashjian, A. H. (2012) · Cited by 469
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455 · cited 2×
“The incidence of acute withdrawal is dose-and duration-dependent, ranging from approximately 30% to 100% [22].”
The Discovery of Fluoxetine Hydrochloride (Prozac)
Wong, D. T., Perry, K. W., & Bymaster, F. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1821 · Cited by 418
Withdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369 · cited 5×
“…perceptual abnormalities, dysphoria [52], trembling, nausea, vomiting, palpitations [40], headache, sweating, sensory disturbances, fear, fatigue [30], enuresis, disinhibition, aggression, impaired memory, weight loss, and ataxia [46] were reported along with the more common acute withdrawal…”
InfluentialWithdrawal from long-term benzodiazepine treatment
Petursson, H., & Lader, M. H. (1981) · BMJ · doi:10.1136/bmj.283.6292.643 · Cited by 367 · cited 3×
“Acute withdrawal symptoms occurred in up to 100% of participants from studies found in this scoping review [52,61,62], but prolonged symptoms were less frequently reported, occurring in approximately 30% of benzodiazepine patients [17,54,69].”
Brandt, J., & Leong, C. (2017) · Drugs in R&D · doi:10.1007/s40268-017-0207-7 · Cited by 356 · cited 1×
“As exposure to these drugs increased, so did reports of adverse events, especially the risks of serious acute withdrawal reactions [8].”
Withdrawal reactions from chlordiazepoxide (?Librium?)
Hollister, L. E., Motzenbecker, F. P., & Degan, R. O. (1961) · Psychopharmacologia · doi:10.1007/bf00429621 · Cited by 340 · cited 1×
“In a clinical study, dependence and withdrawal problems were associated with benzodiazepines within one year after their introduction [3].”
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332 · cited 2×
“Acute withdrawal symptoms occurred in up to 100% of participants from studies found in this scoping review [52,61,62], but prolonged symptoms were less frequently reported, occurring in approximately 30% of benzodiazepine patients [17,54,69].”
Benzodiazepine withdrawal: an unfinished story.
Ashton, H. (1984) · BMJ · doi:10.1136/bmj.288.6424.1135 · Cited by 291 · cited 2×
“This detailed case series reported that all 12 patients developed new symptoms after benzodiazepine cessation that lasted at least six months after drug discontinuation [16]. and reproduction in any medium, provided the original author and source are credited.”
Gradual Withdrawal of Diazepam after Long-Term Therapy
Tyrer, P., Owen, R., & Dawling, S. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92355-3 · Cited by 271 · cited 6×
“Acute withdrawal symptoms occurred in up to 100% of participants from studies found in this scoping review [52,61,62], but prolonged symptoms were less frequently reported, occurring in approximately 30% of benzodiazepine patients [17,54,69].”
InfluentialManagement of benzodiazepine misuse and dependence
Brett, J., & Murnion, B. (2015) · Australian Prescriber · doi:10.18773/austprescr.2015.055 · Cited by 260
The benzodiazepine withdrawal syndrome
PÉTURSSON, H. (1994) · Addiction · doi:10.1111/j.1360-0443.1994.tb03743.x · Cited by 246
Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal
Bateson, A. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396681 · Cited by 240 · cited 1×
“Nevertheless, benzodiazepines are not indicated for the long-term treatment of anxiety, insomnia, or stress, for which they are most often prescribed [81–83].”
Long-term Therapeutic Use of Benzodiazepines: II. Effects of Gradual Taper
Schweizer, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220024003 · Cited by 191 · cited 3×
“…studies were insomnia [30,36,40,55,59,67], generalized anxiety disorder [32,34,45,50,54,65,68], and anxiety with or without panic attacks [30,36,48,54,59,65], although studies noted the inclusion of other patients with indications such as bereavement [40] and major depressive disorder [40,65].”
CURRAN, H. V., COLLINS, R., FLETCHER, S., KEE, S. C. Y., WOODS, B., & ILIFFE, S. (2003) · Psychological Medicine · doi:10.1017/s0033291703008213 · Cited by 190
Systematic review of catatonia treatment
Pelzer, A., van der Heijden, F., & den Boer, E. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s147897 · Cited by 183
Protracted withdrawal syndromes from benzodiazepines
Ashton, H. (1991) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(91)90023-4 · Cited by 170 · cited 3×
“However, earlier literature had described a separate and distinct condition of “prolonged neurological dysfunction [14,15].””
Cognitive impairment in long-term benzodiazepine users
Golombok, S., Moodley, P., & Lader, M. (1988) · Psychological Medicine · doi:10.1017/s0033291700007911 · Cited by 167 · cited 3×
“The most common indications for benzodiazepine use in these studies were insomnia [30,36,40,55,59,67], generalized anxiety disorder [32,34,45,50,54,65,68], and anxiety with or without panic attacks [30,36,48,54,59,65], although studies noted the inclusion of other patients with indications such as…”
Offidani, E., Guidi, J., Tomba, E., & Fava, G. A. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000353198 · Cited by 166
Benzodiazepine dependence and its treatment with low dose flumazenil
Hood, S. D., Norman, A., Hince, D. A., Melichar, J. K., & Hulse, G. K. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12023 · Cited by 165
Benzodiazepine withdrawal: outcome in 50 patients
ASHTON, H. (1987) · British Journal of Addiction · doi:10.1111/j.1360-0443.1987.tb01529.x · Cited by 160 · cited 3×
“Ashton later reported on a cohort of 50 patients [14].”
Voshaar, R. C. O., Gorgels, W. J. M. J., Mol, A. J. J., Van Balkom, A. J. L. M., Van De Lisdonk, E. H., Breteler, M. H. M., Van Den Hoogen, J. M., & Zitman, F. G. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.6.498 · Cited by 154
López-Muñoz, F., Álamo, C., & García-García, P. (2011) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2011.01.002 · Cited by 144 · cited 1×
“In 1960, the first benzodiazepine, chlordiazepoxide (Librium), was released to market and became the most-prescribed drug in the United States until it was eclipsed by another benzodiazepine, diazepam (Valium) [2].”
Acute overdosage with benzodiazepine derivatives
Greenblatt, D. J., ALLEN, M. D., Noel, B. J., & Shader, R. I. (1977) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1977214497 · Cited by 141
Schweizer, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810290060012 · Cited by 138
Greenblatt, D. J., & Shader, R. I. (1974) · New England Journal of Medicine · doi:10.1056/nejm197411072911906 · Cited by 138
Pharmacological Treatment of Insomnia.
(2015) · PubMed Central · Cited by 109
Lack of cognitive recovery following withdrawal from long-term benzodiazepine use
Tata, P. R., Rollings, J., Collins, M., Pickering, A., & Jacobson, R. R. (1994) · Psychological Medicine · doi:10.1017/s0033291700026969 · Cited by 97 · cited 1×
“In one study of prolonged symptoms in 20 benzodiazepine users matched to controls, 100% of the benzodiazepine patients had neurologic symptoms at six months after complete drug cessation [51].”
Efficacy evaluation of clonazepam for symptom remission in burning mouth syndrome: a meta‐analysis
Cui, Y., Xu, H., Chen, F., Jl, L., Jiang, L., Zhou, Y., & Chen, Q. (2015) · Oral Diseases · doi:10.1111/odi.12422 · Cited by 94
Time course for development of benzodiazepine tolerance and physical dependence
Rosenberg, H. C., & Chiu, T. H. (1985) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(85)90038-7 · Cited by 90
Long-term benzodiazepine users 3 years after participation in a discontinuation program
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.6.757 · Cited by 87
Murphy, S. M., Owen, R., & Tyrer, P. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.4.529 · Cited by 77 · cited 1×
“The most common indications for benzodiazepine use in these studies were insomnia [30,36,40,55,59,67], generalized anxiety disorder [32,34,45,50,54,65,68], and anxiety with or without panic attacks [30,36,48,54,59,65], although studies noted the inclusion of other patients with indications such as…”
Greenblatt, D. J., & Shader, R. I. (1974) · New England Journal of Medicine · doi:10.1056/nejm197412052912308 · Cited by 71
Pharmacological Treatment of Insomnia
Schweitzer, P. K., & Feren, S. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-41400-3_7 · Cited by 71
Depression following withdrawal from long-term benzodiazepine use: a report of four cases
Olajide, D., & Lader, M. (1984) · Psychological Medicine · doi:10.1017/s0033291700019899 · Cited by 69 · cited 1×
“Months or years after benzodiazepine discontinuation, a subset of patients experienced mild to severe, even debilitating, symptoms unrelated to their prior condition, such as tinnitus, gastrointestinal symptoms, fatigue, and anxiety that do not meet criteria for another diagnosis [47,50,52,54.]”
Cantopher, T., Olivieri, S., Cleave, N., & Edwards, J. G. (1990) · British Journal of Psychiatry · doi:10.1192/bjp.156.3.406 · Cited by 67
Hadley, S. J., Mandel, F. S., & Schweizer, E. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111405360 · Cited by 66 · cited 1×
“…most common indications for benzodiazepine use in these studies were insomnia [30,36,40,55,59,67], generalized anxiety disorder [32,34,45,50,54,65,68], and anxiety with or without panic attacks [30,36,48,54,59,65], although studies noted the inclusion of other patients with indications such as…”
Ashton, C. H., Rawlins, M. D., & Tyrer, S. P. (1990) · British Journal of Psychiatry · doi:10.1192/bjp.157.2.232 · Cited by 66 · cited 4×
“Acute withdrawal symptoms occurred in up to 100% of participants from studies found in this scoping review [52,61,62], but prolonged symptoms were less frequently reported, occurring in approximately 30% of benzodiazepine patients [17,54,69].”
InfluentialPsychometric performance during withdrawal from long-term benzodiazepine treatment
Petursson, H., Gudjonsson, G. H., & Lader, M. H. (1983) · Psychopharmacology · doi:10.1007/bf00427575 · Cited by 62 · cited 1×
“…studies were insomnia [30,36,40,55,59,67], generalized anxiety disorder [32,34,45,50,54,65,68], and anxiety with or without panic attacks [30,36,48,54,59,65], although studies noted the inclusion of other patients with indications such as bereavement [40] and major depressive disorder [40,65].”
Physician Withdrawal Checklist (PWC-20)
Rickels, K., Garcia-Espana, F., Mandos, L. A., & Case, G. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31817efbac · Cited by 59 · cited 1×
“The most frequently used list of anxiolytic-associated symptoms is the Physician Withdrawal Checklist (PWC-20), but anecdotal reports of benzodiazepine-associated symptoms have appeared in the literature as well [22,74].”
Curran, H. V., Bond, A., O'Sullivan, G., Bruce, M., Marks, I., Lelliot, P., Shine, P., & Lader, M. (1994) · Psychological Medicine · doi:10.1017/s0033291700029056 · Cited by 54
Delle Chiaie, R., Pancheri, P., Casacchia, M., Stratta, P., Kotzalidis, G. D., & Zibellini, M. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502000-00003 · Cited by 53
An evaluation of persisting cognitive effects after withdrawal from long-term benzodiazepine use
BARKER, M. J., GREENWOOD, K. M., JACKSON, M., & CROWE, S. F. (2005) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617705050332 · Cited by 53
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
Rickels, K., Lucki, I., Schweizer, E., Garcia-Espana, F., & Case, W. G. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199904000-00003 · Cited by 49
Quaglio, G., Pattaro, C., Gerra, G., Mathewson, S., Verbanck, P., Des Jarlais, D. C., & Lugoboni, F. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.02.008 · Cited by 48 · cited 1×
“The acute withdrawal syndrome following cessation of chronic benzodiazepine exposure has been well described [19–21].”
Recent Advances and Review on Treatment of Stiff Person Syndrome in Adults and Pediatric Patients
Bhatti, A. B., & Gazali, Z. A. (2015) · Cureus · doi:10.7759/cureus.427 · Cited by 47 · cited 1×
“…system, this is not to trivialize the importance of benzodiazepines for their specific indications: long-term treatment of acute movement disorders such as catatonia, stiff-person syndrome, status dystonicus and, more rarely, seizure disorders and burning mouth syndrome (clonazepam only) [75–80].”
A follow‐up study of patients treated for benzodiazepine dependence
Golombok, S., Higgitt, A., Fonagy, P., Dodds, S., Saper, J., & Lader, M. (1987) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1987.tb02724.x · Cited by 46
Differential acute psychomotor and cognitive effects of diazepam on long-term benzodiazepine users
Gorenstein, C., Bernik, M. A., & Pompéia, S. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199409000-00002 · Cited by 45
Feasibility of discontinuing chronic benzodiazepine use in nursing home residents: a pilot study
Bourgeois, J., Elseviers, M. M., Bortel, L. M. V., Petrović, M., & Stichele, R. V. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1725-7 · Cited by 44
O'Connor, K. P., Marchand, A., Bélanger, L., Mainguy, N., Landry, P., Savard, P., Turcotte, J., Dupuis, G., Harel, F., & Lachance, L. (2004) · Addictive Behaviors · doi:10.1016/j.addbeh.2004.01.001 · Cited by 44 · cited 3×
“…studies were insomnia [30,36,40,55,59,67], generalized anxiety disorder [32,34,45,50,54,65,68], and anxiety with or without panic attacks [30,36,48,54,59,65], although studies noted the inclusion of other patients with indications such as bereavement [40] and major depressive disorder [40,65].”
Protracted Tinnitus after Discontinuation of Long-Term Therapeutic Use of Benzodiazepines
BUSTO, U., FORNAZZARI, L., & NARANJO, C. A. (1988) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198810000-00010 · Cited by 43 · cited 1×
“…acute withdrawal period, the emergence of de novo symptoms, including akathisia, pelvic pain, tinnitus, suicidal ideation, reduced appetite, weight loss, perceptual disturbances, paresthesia, depersonalization, derealization, numbness, and involuntary movements have been reported [30,31,50,52,61].”
Martin, P. R., Kapur, B. M., Whiteside, E. A., & Sellers, E. M. (1979) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1979262256 · Cited by 42 · cited 2×
“There are established treatment protocols for benzodiazepine acute withdrawal syndrome [10,72,73].”
Self-citationBelleville, G., & Morin, C. M. (2008) · Health Psychology · doi:10.1037/0278-6133.27.2.239 · Cited by 41
Tönne, U., Hiltunen, A. J., Vikander, B., Engelbrektsson, K., Bergman, H., Bergman, I., Leifman, H., & Borg, S. (1995) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1995.tb09786.x · Cited by 40 · cited 1×
“In the initial round of testing, benzodiazepine patients had test scores that showed impaired intelligence and impaired nonverbal memory versus controls but at one year, scores were similar to controls, suggesting that neurologic deficits may be at least partly, albeit slowly, reversible [66].”
A Controlled Trial of Ondansetron, a 5-HT3 Antagonist, in Benzodiazepine Discontinuation
Romach, M. K., Kaplan, H. L., Busto, U. E., Somer, G., & Sellers, E. M. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199804000-00004 · Cited by 40
Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey
Reid Finlayson, A. J., Macoubrie, J., Huff, C., Foster, D. E., & Martin, P. R. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221082386 · Cited by 40 · cited 2×
“Reports emerged of prolonged problematic clinical symptoms that could persist after completion of the acute withdrawal syndrome, enduring for months or even years after benzodiazepine cessation [12].”
Self-citationLong-term effects of alprazolam on memory: a 3·5 year follow-up of agoraphobia/panic patients
KILIÇ, C., CURRAN, H. V., NOSHIRVANI, H., MARKS, I. M., & BA[Sogon];OĞLU, M. (1999) · Psychological Medicine · doi:10.1017/s003329179800734x · Cited by 39
Impairment of performance associated with long-term use of benzodiazepines
Gorenstein, C., Bernik, M. A., Pompéia, S., & Marcourakis, T. (1995) · Journal of Psychopharmacology · doi:10.1177/026988119500900404 · Cited by 38 · cited 1×
“At both time points, the benzodiazepine patients had significantly worse scores than the controls [38].”
Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey
Ritvo, A. D., Foster, D. E., Huff, C., Finlayson, A. J. R., Silvernail, B., & Martin, P. R. (2023) · PLOS ONE · doi:10.1371/journal.pone.0285584 · Cited by 38 · cited 5×
“The majority of respondents also reported adverse life consequences, such as the loss of home or business or failed relationships [13].”
InfluentialSelf-citationBenzodiazepine tapering: A prospective study
Vikander, B., Koechling, U. M., Borg, S., Tönne, U., & Hiltunen, A. J. (2010) · Nordic Journal of Psychiatry · doi:10.3109/08039481003624173 · Cited by 37 · cited 2×
“The most common indications for benzodiazepine use in these studies were insomnia [30,36,40,55,59,67], generalized anxiety disorder [32,34,45,50,54,65,68], and anxiety with or without panic attacks [30,36,48,54,59,65], although studies noted the inclusion of other patients with indications such as…”
The natural history of tolerance to the benzodiazepines
Higgitt, A., Fonagy, P., & Lader, M. (1988) · Psychological Medicine. Monograph Supplement · doi:10.1017/s0264180100000412 · Cited by 37
The prolonged benzodiazepine withdrawal syndrome: anxiety or hysteria?
Higgitt, A., Fonagy, P., Toone, B., & Shine, P. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb01375.x · Cited by 35 · cited 6×
“Acute withdrawal symptoms occurred in up to 100% of participants from studies found in this scoping review [52,61,62], but prolonged symptoms were less frequently reported, occurring in approximately 30% of benzodiazepine patients [17,54,69].”
InfluentialrTMS and tDCS for the treatment of catatonia: A systematic review
Hansbauer, M., Wagner, E. M., Strube, W., Röh, A., Padberg, F., Keeser, D., Falkai, P., & Hasan, A. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.05.028 · Cited by 34
Benzodiazepine withdrawal in general practice.
(1982) · PubMed Central · Cited by 33
A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal
Lader, M. H., & Morton, S. V. (1992) · Journal of Psychopharmacology · doi:10.1177/026988119200600303 · Cited by 33 · cited 2×
“Acute withdrawal symptoms occurred in up to 100% of participants from studies found in this scoping review [52,61,62], but prolonged symptoms were less frequently reported, occurring in approximately 30% of benzodiazepine patients [17,54,69].”
Chronic diazepam administration increases the expression of Lcn2 in the CNS
Furukawa, T., Shimoyama, S., Miki, Y., Nikaido, Y., Koga, K., Nakamura, K., Wakabayashi, K., & Ueno, S. (2017) · Pharmacology Research & Perspectives · doi:10.1002/prp2.283 · Cited by 31 · cited 1×
“Neurotoxicity is a complex condition which may or may not be reversible and which can manifest differently in different patients [91–93].”
Evaluation of the efficacy of treatment modalities in burning mouth syndrome—A systematic review
Ślebioda, Z., Łukaszewska‐Kuska, M., & Dorocka−Bobkowska, B. (2020) · Journal of Oral Rehabilitation · doi:10.1111/joor.13102 · Cited by 27 · cited 1×
“…system, this is not to trivialize the importance of benzodiazepines for their specific indications: long-term treatment of acute movement disorders such as catatonia, stiff-person syndrome, status dystonicus and, more rarely, seizure disorders and burning mouth syndrome (clonazepam only) [75–80].”
Furukawa, T., Nikaido, Y., Shimoyama, S., Masuyama, N., Notoya, A., & Ueno, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.777404 · Cited by 27
Protracted Benzodiazepine Withdrawal Syndrome Mimicking Psychotic Depression
Modell, J. G. (1997) · Psychosomatics · doi:10.1016/s0033-3182(97)71493-2 · Cited by 24
A Case of Stiff Person Syndrome
Zdziarski, P. (2015) · Medicine · doi:10.1097/md.0000000000000954 · Cited by 23
Enduring neurological sequelae of benzodiazepine use: an Internet survey
Huff, C., Finlayson, A. J. R., Foster, D. E., & Martin, P. R. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221145561 · Cited by 18 · cited 2×
“Consistent with other published studies and clinical observations, this scoping review showed that some people can discontinue benzodiazepines even after prolonged exposure with relatively little problem [12,13,23].”
Self-citationO'Sullivan, G. H., Swinson, R., Kuch, K., Marks, I. M., Basoglu, M., & Noshirvani, H. (1996) · Journal of Psychopharmacology · doi:10.1177/026988119601000204 · Cited by 10 · cited 1×
“…nausea, vomiting, palpitations [40], headache, sweating, sensory disturbances, fear, fatigue [30], enuresis, disinhibition, aggression, impaired memory, weight loss, and ataxia [46] were reported along with the more common acute withdrawal symptoms of insomnia, anxiety, and nervousness [40].”
Buspirone treatment as an aid to benzodiazepine withdrawal
Morton, S., & Lader, M. (1995) · Journal of Psychopharmacology · doi:10.1177/026988119500900407 · Cited by 10
(2023) · PubMed · Cited by 9
Abstinence Syndrome from Therapeutic Doses of Oxazepam *
Wilbur, R., & Kulik, A. V. (1983) · The Canadian Journal of Psychiatry · doi:10.1177/070674378302800412 · Cited by 8
Jung, M. E., Metzger, D. B., & Hall, J. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172873 · Cited by 8 · cited 1×
“Neurotoxicity is a complex condition which may or may not be reversible and which can manifest differently in different patients [91–93].”
Cassano, G., Petracca, A., Borghi, C., Chiroli, S., Didoni, G., & Garreau, M. (1996) · European Psychiatry · doi:10.1016/0924-9338(96)84786-9 · Cited by 7 · cited 1×
“The most common indications for benzodiazepine use in these studies were insomnia [30,36,40,55,59,67], generalized anxiety disorder [32,34,45,50,54,65,68], and anxiety with or without panic attacks [30,36,48,54,59,65], although studies noted the inclusion of other patients with indications such as…”
Delusional Depression following Benzodiazepine Withdrawal
Keshavan, M. S., Moodley, P., Eales, M. J., Joyce, E. M., & Yeragani, V. K. (1988) · The Canadian Journal of Psychiatry · doi:10.1177/070674378803300709 · Cited by 3
Surviving Benzodiazepines: A Patient’s and Clinician’s Perspectives
Silvernail, C. M., & Wright, S. L. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02055-y · Cited by 3 · cited 3×
“Months or years after benzodiazepine discontinuation, a subset of patients experienced mild to severe, even debilitating, symptoms unrelated to their prior condition, such as tinnitus, gastrointestinal symptoms, fatigue, and anxiety that do not meet criteria for another diagnosis [47,50,52,54.]”
Research works printed but not linked: 5
- Foster D. Benzo Free: The World of Anti-Anxiety Drugs and the Reality of Withdrawal. Erie, Colorado: Denim Mountain Press; 2018. 309 p.
- Shade K, Ritvo A, Silvernail B, Martin P, Foster D, Huff C, et al. Benzodiazepine induced neurological dysfunction: an overview of adverse long-term neurological consequences following chronic use of benzodiazepines: a scoping review protocol. 2023. · DOI · Paper page
- Peperkamp P, Goodman L. The discontinuation of lorazepam and diazepam following sub-chronic therapy in anxious outpatients. J Drug Dev. 1993; 6(4): 171– 82.
- Rosenberg HC, Chiu TH. Time course for development of benzodiazepine tolerance and physical dependence. Neurosci Biobehav Rev. 1985; 9(1): 123– 31. doi: 10.1016/0149-7634(85)90038-7 2858077 · DOI · Paper page
- The Maudsley desprescribing guidelines: Antidepressants, benzodiazepines, gabapentindoids and Z-drugs. Wiley-Blackwell. 2024.
Cited by
Pharmacological principles for safe benzodiazepine and Z-drug dose reduction
Horowitz, M., Lamberson, N., Brandt, J., Framer, A., Shapiro, B., Sørensen, A., Cadogan, C., Ritvo, A., & Taylor, D. (2026) · Psychological Medicine · doi:10.1017/s0033291726104887
“…Dysfunction ’ (BIND) as more appropriate, recognizing that such protracted symptoms often do not respond to re-instatement (Ritvo et al., 2023; Shade et al., 2025), like similar post-cessation-induced neurological dysfunction seen from other classes of psychiatric drugs (Horowitz &…”
Self-citationAyala, J. R. S., Armas, D. A., García, V. H., Aguirre‐Jaime, A., Gutiérrez, A. J., Paz, S., de la Torre, A. H., & Rubio, C. (2025) · Pharmacy · doi:10.3390/pharmacy13060181 · Cited by 1
“Given that abrupt withdrawal can cause rebound symptoms [44], structured withdrawal with monitoring is necessary [3].”
Toward clarifying ASAM’s inpatient and residential benzodiazepine tapering recommendations
Blazes, C. K., Leung, S., Chervin, D. D., & Silvernail, B. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1857354
Self-citationLeistungssteigernde Mittel im Alltag und im Arbeitsleben
Milin, S., Ebel, F. A., & Schäfer, I. (2026) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-026-04254-2
“…darunter Rebound-Effekte (verstärkte Rückkehr der Symptome, die Anlass für den Gebrauch der Substanz waren, nach Abklingen der Wirkung), gesundheitliche Folgen von Mischkonsum sowie Abhängigkeits-und Toleranzentwicklung, insbesondere bei wiederholtem Gebrauch ohne me-dizinische Begleitung [34–36].”
Chakraborty, W., Anand, A., & Roy, K. K. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111846
Metadata
- Authors
- Shade, K. N., Ritvo, A. D., Silvernail, B., Finlayson, A. J. R., Bressi, J. E., Foster, D. E., Martin, I. J., Piper, C., & Martin, P. R.
- Affiliations
- University of Colorado Anschutz (US)
- Vanderbilt University Medical Center (US)
- Yale University (US)
- Corresponding author
- Shade, Kyla N.
- Ritvo, Alexis D.
- Silvernail, Bernard
- Finlayson, A. J. Reid
- Bressi, Jolene E.
- Foster, D. E.
- Martin, Ian J.
- Piper, Christi
- Martin, Peter R.
- ORCID
- Venue
- PLOS One
- Publisher
- Public Library of Science (PLoS)
- Published
- 2025-08-28
- Volume
- 20
- Issue
- 8
- Pages
- e0330277
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC12393751
- OpenAlex
- W4413786647
- Cited by
- 7
- References
- 88
- Citations by year
- 2026: 6 · 2025: 1
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- benzodiazepines, benzodiazepine withdrawal, benzodiazepine discontinuation, neurotoxicity, benzodiazepine dependence
- MeSH terms
- Benzodiazepines, Humans, Nervous System Diseases, Substance Withdrawal Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.